Paper - WANFANG MED ONLINE

You Position: Home > Paper

Research advances in pathogenesis and diagnostic markers of drug-induced liver injury

( views:0, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 13

DOI:: 10.11569/wcjd.v29.i13.726

Key Word:: 药物性肝损伤;发病机制;生物标志物

Abstract：药物性肝损伤(drug-induced liver injury,DILI)的发病机制复杂,涉及多种因素,迄今尚不十分明确,近年来学者们开展了许多关于DILI发病机制的相关研究.由于DILI其临床表现多样性且没有具体统一的诊断标准,因而增加了DILI诊断及治疗的复杂性.为加强对DILI的认识,本文总结了DILI的发病机制及诊断标志物的最近研究进展.

Reference

[1]中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].2015,(11).
[2]耿文静,刘晖,丁惠国.药物性肝损伤的潜在机制、病理特点及生物标志物[J].2019,(4).
[3]袁苏榆,丁洋.生物标志物在对乙酰氨基酚致肝损伤治疗中的应用[J].2019,(2).
[4]王海珍,李秀惠.药物性肝损伤发病机制研究进展[J].2018,(4).
[5]沈弢,黄昕,王誉雅,等.我国药物性肝损伤流行病学研究现状[J].2018,(6).
[6]余朋飞,吴桥,段钟平,等.对乙酰氨基酚致药物性肝损伤的机制研究进展[J].2019,(9).
[7]Jiang, J.,Mathijs, K.,Timmermans, L.,etc.Omics-based identification of the combined effects of idiosyncratic drugs and inflammatory cytokines on the development of drug-induced liver injury[J].2017,332.
[8]McGill, Mitchell R.,Jaeschke, Hartmut.Animal models of drug-induced liver injury[J].2019,1865(5).
[9]Bruno, Stieger,Zainab M, Mahdi.Model Systems for Studying the Role of Canalicular Efflux Transporters in Drug-Induced Cholestatic Liver Disease.[J].2017,106(9).
[10]James W. Dear.New biomarkers for drug‐induced liver injury[J].2018,67(6).
[11]Bj?rnsson,E.S.,Bergmann,O.M.,Bj?rnsson,H.K.,etc.Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of iceland[J].2013,144(7).
[12]Jack,Uetrecht.Mechanistic Studies of Idiosyncratic DILI: Clinical Implications.[J].2019,10.
[13]Rachel J. Church,Paul B. Watkins.The transformation in biomarker detection and management of drug‐induced liver injury[J].2017,37(11).
[14]Neuman, Manuela G..Biomarkers of Drug-Induced Liver Toxicity[J].2019,41(2).
[15]Robert John Fontana,Elizabeth Theresa Cirulli,Jiezhun Gu,etc.The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine[J].2018,69(6).
[16]Chofit Chai,Mila Rivkin,Liav Berkovits,etc.Metabolic Circuit Involving Free Fatty Acids, microRNA 122, and Triglyceride Synthesis in Liver and Muscle Tissues[J].2017,153(5).
[17]Morgan,R.E.,vanStaden,C.J.,Chen,Y.,etc.A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development[J].2013,136(1).
[18]Keisuke, Goda,Akio, Kobayashi,Akemi, Takahashi,etc.Evaluation of the Potential Risk of Drugs to Induce Hepatotoxicity in Human-Relationships between Hepatic Steatosis Observed in Non-Clinical Toxicity Study and Hepatotoxicity in Humans.[J].2017,18(4).
[19]Cheng,Zhang,Ning,Wang,Yu,Xu,etc.Molecular Mechanisms Involved in Oxidative Stress-Associated Liver Injury Induced by Chinese Herbal Medicine: An Experimental Evidence-Based Literature Review and Network Pharmacology Study.[J].1909,19(9).
[20]Victor J. Navarro,Ikhlas Khan,Einar Björnsson,etc.Liver injury from herbal and dietary supplements[J].2017,65(1).
[21]Martin Murphy BV,Holt MP,Ju C.The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice.[J].2010,192(3).
[22]Koichi Arakawa,Yugo Ikeyama,Tomoyuki Sato,etc.Functional modulation of liver mitochondria in lipopolysaccharide/drug co-treated rat liver injury model[J].2019,44(12).
[23]Priya,Grewal,Jawad,Ahmad.Severe liver injury due to herbal and dietary supplements and the role of liver transplantation.[J].2019,25(46).
[24]Real Mark,Barnhill Michele S.,Higley Cory,etc.Drug-Induced Liver Injury: Highlights of the Recent Literature[J].2018,42(3).
[25]于歆,李晓冰,何晓静,等.药物性肝损伤的机制[J].2017,(10).
[26]Church, Rachel J.,Watkins, Paul B..In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials[J].2018,243(3).
[27]Mosedale, M.,Watkins, P. B..Drug-Induced Liver Injury: Advances in Mechanistic Understanding That Will Inform Risk Management[J].2017,101(4).
[28]Hui Ye,Leonard J Nelson,Manuel Gómez del Moral,etc.Dissecting the molecular pathophysiology of drug-induced liver injury[J].2018,(13).
[29]Bjornsson E,Olsson R.Suspected drug-induced liver fatalities reported to the WHO database.[J].2006,38(1).
[30]de Boer, Ynto S.,Sherker, Averell H..Herbal and Dietary Supplement-Induced Liver Injury[J].2017,21(1).
[31]Maiuri, Ashley R.,Roth, Robert A.,Ganey, Patricia E..Idiosyncratic Drug-Induced Liver Injury: Is Drug-Cytokine Interaction the Linchpin?[J].2017,360(2).
[32]Rivkin, Mila,Simerzin, Alina,Zorde-Khvalevsky, Elina,etc.Inflammation-Induced Expression and Secretion of MicroRNA 122 Leads to Reduced Blood Levels of Kidney-Derived Erythropoietin and Anemia[J].2016,151(5).
[33]A, Licata,M G, Minissale,V, Calvaruso,etc.A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort.[J].2017,21(1 Suppl).
[34]Wan-Na Yang,Li-Li Pang,Ji-Yuan Zhou,etc.Single-nucleotide polymorphisms of HLA and Polygonum multiflorum-induced liver injury in the Han Chinese population[J].2020,(12).
[35]Lee, William M.,Sanders, Corron,Dahl, Benny,etc.Plasma osteopontin in acute liver failure[J].2015,73(2).
[36]孟敏,庄彦华,宋传芳,等.药物性肝损害发病机制的研究进展[J].2017,(68).
[37]Luís Filipe Azevedo,Manuela Araújo,Ana Miguel,etc.Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis.[J].2012,21(11).
[38]Lazarska, Katarzyna E.,Dekker, Stefan J.,Vermeulen, Nico P. E.,etc.Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism[J].2018,284.
[39]Rachel J. Church,Gerd A. Kullak‐Ublick,Jiri Aubrecht,etc.Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort[J].2019,69(2).
[40]Mitchell R,McGill,Hartmut,Jaeschke.Biomarkers of drug-induced liver injury.[J].2019,85.
[41]Rachel J. Church,Paul B. Watkins.Serum biomarkers of drug‐induced liver injury: Current status and future directions[J].2019,20(1).
[42]Medina-Caliz, Inmaculada,Robles-Diaz, Mercedes,Garcia-Munoz, Beatriz,etc.Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury[J].2016,65(3).
[43]Ammar Hassan,Robert J. Fontana.The diagnosis and management of idiosyncratic drug‐induced liver injury[J].2019,39(1).
[44]Raul J,Andrade,Naga,Chalasani,Einar S,Björnsson,etc.Drug-induced liver injury.[J].2019,5(1).
[45]Garcia-Cortes Miren,Robles-Diaz Mercedes,Stephens Camilla,etc.Drug induced liver injury: an update[J].2020,94(10).
[46]Mitchell R. McGill,Hartmut Jaeschke.Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation[J].2018,18(7/12).
[47]严婉妮,程虹.生物标志物在药物性肝损伤中应用的研究进展[J].2019,(6).
[48]Mónica,Teixeira,Sara,Macedo,Tânia,Batista,etc.Flucloxacillin-Induced Hepatotoxicity - Association with HLA-B*5701.[J].2020,66(1).
[49]Ali, Izna,Welch, Matthew A.,Lu, Yang,etc.Identification of novel MRP3 inhibitors based on computational models and validation using an in vitro membrane vesicle assay[J].2017,103.
[50]McEuen, Kristin,Borlak, Juergen,Tong, Weida,etc.Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury[J].2017,18(7).
[51]Li, Xuesong,Jin, Shasha,Fan, Yujuan,etc.Association of HLA-C*03:02 with methimazole-induced liver injury in Graves' disease patients[J].2019,117(117).
[52]Kaliyaperumal, Kalaiyarasi,Grove, Jane I.,Delahay, Robin M.,etc.Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications[J].2018,69(4).
[53]Andrade, Raul J.,Aithal, Guruprasad P.,Bjornsson, Einar S.,etc.EASL Clinical Practice Guidelines: Drug-induced liver injury[J].2019,70(6).